The Value of Peripheral Arterial Resistive Index in Evaluation of Tissue Perfusion in Patients With Septic Shock

June 12, 2023 updated by: Bezmialem Vakif University

In patients with septic shock, routine arterial blood pressure and central venous pressure are monitored in ICU. Conventional methods such as blood pressure and central venous pressure in septic patients cannot provide sufficient information in the follow-up due to the body's compensation mechanisms. The systemic vascular resistance index, which can be measured invasively or non-invasively with advanced hemodynamic monitoring methods, is a parameter that plays an important role in the management of septic patients.

Resistive index (Pourcelot Index) is an ultrasonic measurement method used to evaluate tissue perfusion and microcirculation. Since peripheral tissue perfusion is impaired in septic patients, the investigators think resistive index may be useful for management of sepsis. There are studies in the literature on the use of resistive index in the follow-up of patients.

The study will be about whether there is a correlation between the systemic vascular resistance index measured by cardiac output measurement, which is one of the advanced monitoring methods routinely used in the group requiring mechanical ventilation support in patients with septic shock, and the peripheral arterial resistive index, which is routinely used to evaluate tissue perfusion and microcirculation.

Study Overview

Detailed Description

Sepsis is not a specific disease but abnormal response for infection, leading to organ dysfunction. It is a clinical syndrome consisting of biological, biochemical, and physiological abnormalities which pathophysiology has not yet been fully determined. Sepsis is shaped by pathogenic factors and host factors (eg, gender, race and other genetic determinants, age, comorbidities, environment) and its features evolve over time. What distinguishes sepsis from infection is the presence of abnormal and/or irregular host response and organ dysfunction. It is one of the leading health problems worldwide and one of the leading causes of mortality in hospitalizations. Its estimated that there were 48.9 million cases and 11 million sepsis-related deaths worldwide in 2017, accounting for almost 20% of all global deaths. In an epidemiological study conducted in European intensive care units (ICU), the incidence of sepsis was reported as 38%. Pneumonia, urinary tract, and intra-abdominal infections account for more than 65% of all sepsis cases. According to the Surviving Sepsis Campaign (SSC) data, mortality rates in sepsis are 41% in Europe and 28.3% in the United States (USA). In a multicenter study involving 101,064 critically ill patients in Australia and New Zealand between 2002 and 2012, mortality rates due to sepsis were found to decrease over the years and finally to 18-20%. Recognition of sepsis, which can be very mortal, especially if not recognized fast and treatment not started, requires urgent attention.

Due to the lack of treatment options targeting microcirculatory and mitochondrial dysfunction, treatment has been focused on correcting the macrocirculatory dysfunction in addition to treating the underlying cause during septic shock. In the early phase of septic shock, external losses and hypovolemia are seen because of capillary leakage. Therefore, fluid resuscitation is often recommended to increase cardiac output and improve tissue perfusion. However, large boluses of fluids (>30 ml/kg) do not reliably increase blood pressure, urine output, and end-organ perfusion, and may lead to iatrogenic damage. Sepsis is characterized by disruptions in tissue perfusion and abnormal peripheral vascular resistance, because of disruptions in microcirculation. therefore, improving vascular function and organ damage is crucial in the management of septic shock. For treatment of hypotension; the need for fluid should be determined and the right amount of fluid resuscitation should be provided to the right patient.

Systemic vascular resistance is a parameter that depends on the afterload of the heart and corresponds to the resistance of the heart while it is working. It is the resistance the heart has to overcome to pump blood to the rest of the body except the lungs. The systemic vascular resistance index (SVRI) is defined as the ratio of mean arterial pressure (MAP) and central venous pressure (CVP) to cardiac index (CI) (SVRI= 80 x (MAP-CVP) / CI). In general, SVRI is proportional to MAP. It decreases due to vasodilation in septic patients. Compared to previous studies, lower SVRI in septic shock was associated with adverse outcomes and increased mortality. Invasive methods such as pulmonary artery catheters or relatively expensive methods such as PICCO are required for SVRI measurement.

Can a more cost-effective and rapid alternative to the systemic vascular resistance index measured by expensive or high-risk methods be found? Ultrasound, as modern stethoscope, is a need especially in every 3 level ICU.

The resistive index (RI) (Pourcelot index) is a noninvasive measurement used to evaluate vessel compliance with Doppler ultrasound. It is determined by a formula calculated between the systolic peak flow rate (PSV) and the end-diastolic flow rate (EDV) ((PSV-EDV)/PSV). Today RI is using for measure to assess tissue perfusion, particularly on the kidney. Renal RI shows changes in renal intravascular volume and hemodynamics. An inverse relationship has been shown between renal RI and MAP in acute kidney injury. Measurement of RI on the peripheral artery correlated with SVRI in a study of patients who had undergone cardiac surgery.

In this study the investigators will compare RI on radial artery in wrist snuffbox (SBRI) with SVRI for primary outcome. Also compare SBRI with MAP, CVP, diastolic shock index, pleth variability index, delta stroke volume index, central venous oxygen saturation (ScvO2) and partial carbon dioxide gap (Pv-aCO2) for secondary outcome.

Each patient will be followed for sepsis and septic shock. In the investigators ICU all sepsis patients has invasive artery canula for real-time monitoring and central venous catheter for blood sampling and need of vasopressor so there won't be any extra risk for this study. If a septic shock patient needs to mechanically ventilated and meets inclusion criteria, the investigators will carry out measurements just after intubation. Or, a mechanical ventilated patient who has developed septic shock; if patient has no spontaneous breathing effort, the investigators will carry out measurements. Also, arterial and central venous blood samples are taken after intubation or septic shock for every 6 hours, daily complete blood count (CBC), C-reactive protein, renal and hepatic blood analysis, and 2 times per week procalcitonin levels as routine at the hospital where the study is taking place in ICU.

Demographic parameters, physical examination notes (capillary refill time, mottling score, urine output, skin turgor), systolic, diastolic and mean arterial pressure, central venous pressure, arterial and central venous blood gas analysis, CBC and biochemistry blood analysis, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, Sequential Organ Failure Assesment (SOFA) score and Nutrition Risk in the Critically Ill (NUTRIC) Score will be noted. For cardiac output monitoring Baxter Starling non-invasive monitor will be used and all hemodynamic parameters will be noted for study during examination.. For measuring SBRI Philips CX50 ultrasound device L12-3 linear probe will be used. Starling monitors 4 electrodes will be placed as specified by the manufacturer. Masimo Rad-87 probe will place hand index or middle finger. SBRI will measure for three times successive with 1.5 centimeters depth and 3 same measurement will be recorded. At the same time baseline evaluation will be started with Starling monitor and all parameters will be noted. After completion of baseline measurement Starling fluid challenge will be initiated as passive leg raising as specified by manufacturer. This procedure takes 3 minutes to calculate and after 2.5 minutes SBRI will be measured again as described above. At the end of fluid challenge all parameters will be noted.

Study Type

Observational

Enrollment (Actual)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • İstanbul
      • Fatih, İstanbul, Turkey, 34093
        • Bezmialem Vakıf University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Patients who admited to intensive care unit of Bezmialem Vakıf Univesity Hospital

Description

Inclusion Criteria:

  • >18 years old
  • admitted to intensive care for septic shock
  • mechanical ventilated
  • non spontaneous breathing
  • applied invasive artery cannulation (radial, femoral, brachial)
  • applied central venous catheter (jugular, subclavian)
  • SOFA score>2
  • Receiving vasopressor/inotrope support to achieve MAP ≥65 mmHg
  • Blood lactate >2mmol/L

Exclusion Criteria:

  • <18 years old
  • Hypothermia (<35C)
  • Atrial fibrilation/flutter
  • Pace-maker
  • Severe aort valve insufficiency
  • History of aortic and the great arteries adjacent to the aortic arch surgery
  • Bilateral radial artery puncture in last 12 hours
  • Peripheral artery disease
  • Extremity amputation (leg or arm)
  • Wound on forearm
  • Continous Renal Replacement Therapy
  • Spontaneous breath effort

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
septic shock patients
mechanically ventilated septic shock patients
Baxter Starling Monitor for measuring cardiac output and systemic vascular resistance (SVRI) which is using bioreactance technology. We need to place four electrodes on chest wall (upper left, upper right, down left, down right) and input monitor demographic parameters. Also enter mean arterial pressure (MAP) for calculating SVRI so we input MAP every minute.Patient bed set as 45 degree head elevated and legs 0 degree. Just after start measuring, monitor needs to synchronize itself for patient. After synchronisation we start fluid challenge with passive leg raising option. This test has two stages. First stage calculating baseline parameters which takes 3 minutes and second stage is measuring difference with fluid challenge which also takes 3 minutes. At the end of first stage monitor shows to perform passive leg raise and we perform trendelenburg maneuver till head comes to 0 degree. After second stage measurement has finished.
Other Names:
  • Non Invasive Cardiac Output Monitor (NICOM)
We use ultrasonography at the same time with cardiac output monitor in both stages. First we determine the location of radial artery at wrist snuffbox at 1.5 centimeters depth with linear probe and confirm pulsatile flow with color mode. In Starling's baseline stage we measure and calculate resistive index with doppler P-mode in triplex setting 3 times. When received 3 same result successively we noted as SBRI-1. Second measurement is initiated at last 30 seconds of passive leg raising as described before and we noted our measurement as SBRI-2
Other Names:
  • SBRI
  • Snuffbox resistive index
  • Pourcelot index
  • doppler ultrasonography
During all stages Masimo Rad-87 rainbow probe is placed patients index or middle finger and we note PVI-1 and PVI-2 at the same time with SBRI-1 and SBRI-2
Other Names:
  • PVI
  • Rad-87

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
correlation of snuffbox radial artery resistive index and systemic vascular resistance index
Time Frame: 1 hour. As soon as patient meets all of the inclusion criteria
correlation of snuffbox radial artery resistive index and systemic vascular resistance index
1 hour. As soon as patient meets all of the inclusion criteria

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
correlation of snuffbox radial artery resistive index and pleth variability index
Time Frame: 1 hour. As soon as patient meets all of the inclusion criteria
correlation of snuffbox radial artery resistive index and pleth variability index
1 hour. As soon as patient meets all of the inclusion criteria
correlation of snuffbox radial artery resistive index and delta stroke volume index
Time Frame: 1 hour. As soon as patient meets all of the inclusion criteria
correlation of difference in snuffbox radial artery resistive index and delta stroke volume index
1 hour. As soon as patient meets all of the inclusion criteria
correlation of snuffbox radial artery resistive index and diastolic shock index
Time Frame: 1 hour. As soon as patient meets all of the inclusion criteria
correlation of snuffbox radial artery resistive index and diastolic shock index
1 hour. As soon as patient meets all of the inclusion criteria
correlation of snuffbox radial artery resistive index and central vena cava oxygen saturation and partial carbon dioxide pressure gap
Time Frame: 1 hour. As soon as patient meets all of the inclusion criteria
correlation of snuffbox radial artery resistive index and central vena cava oxygen saturation and partial carbon dioxide pressure gap
1 hour. As soon as patient meets all of the inclusion criteria
correlation of snuffbox radial artery resistive index and cardiac power index
Time Frame: 1 hour. As soon as patient meets all of the inclusion criteria
correlation of snuffbox radial artery resistive index and cardiac power index
1 hour. As soon as patient meets all of the inclusion criteria

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2022

Primary Completion (Actual)

March 31, 2023

Study Completion (Actual)

March 31, 2023

Study Registration Dates

First Submitted

May 27, 2023

First Submitted That Met QC Criteria

June 12, 2023

First Posted (Estimated)

June 13, 2023

Study Record Updates

Last Update Posted (Estimated)

June 13, 2023

Last Update Submitted That Met QC Criteria

June 12, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

statistical data will be shared

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Shock, Septic

Clinical Trials on hemodynamic monitoring

Subscribe